The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Senseonics has filed to obtain CE Mark registration for its one-year continuous glucose monitoring (CGM) system, Eversense ...

These days, many devices are programmed through apps on patients’ phones. But the FDA warns that certain phone settings, such ...

Senseonics Holdings, Inc.’s SENS share price has surged by 13.29%, which has investors questioning if this is right time to ...

Gonzaga University and the UW School of Medicine hosted Irl Hirsch to lecture about the future of glucose monitoring.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Continuous Glucose Monitor Data Predicts Type 1 Diabetes Complications Jan. 15, 2025 — Data from continuous glucose monitors can predict nerve, eye and kidney damage caused by type 1 diabetes ...

Transforming global health demands smart chemistry, addressing urgent health challenges through innovative, durable medical ...

Shares of Senseonics Holdings, Inc. (NYSE:SENS – Get Free Report) shot up 8.4% on Friday . The company traded as high as $1.12 and last traded at $1.10. 4,920,939 shares were traded during mid-day ...

For now, those with diabetes or individuals obsessed with leading a healthy lifestyle consider using glucose monitors. However, if equipped with wearable tech, it can help others realize how and when ...